|
Mutation Information
|
Mutation Site
|
R263K |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
IN |
|
Combined Mutation
|
in.R263K+in.T97A;in.Y143C+in.Y143R+in.T97A |
|
Relevant Drug
|
raltegravir (RAL) |
|
Country
|
Africa |
Literature Information
|
PubMed PMID
|
30513108
|
|
Disease
|
HIV infection/AIDS
|
|
Published Year
|
2018 |
|
Journal
|
PLoS medicine |
|
Title
|
Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial. |
|
Author
|
Kityo C,Szubert AJ,Siika A,Heyderman R,Bwakura-Dangarembizi M,Lugemwa A,Mwaringa S,Griffiths A,Nkanya I,Kabahenda S,Wachira S,Musoro G,Rajapakse C,Etyang T,Abach J,Spyer MJ,Wavamunno P,Nyondo-Mipando L,Chidziva E,Nathoo K,Klein N,Hakim J,Gibb DM,Walker AS,Pett SL,REALITY trial team. |
|
Evidence
|
One participant had predicted intermediate-level (mutations T97A+R263K) and two predicted high-level (N155H, T97A+Y143R/C) raltegravir resistance mutations (0.6% of those randomised, accounting for missing genotypes using probability weights).
|
|
|
HIV Mutation Detail Information